Growth story on track Fusion Antibodies, a specialised Contract Research Organisation operating in the field of monoclonal antibody engineering and production, has provided an update on trading for the year ending 31 March 2018. It reports that FY18 revenues are expected to grow sizeably by at least 40% from £1.9m in FY17. This is slightly below expectations, due to the temporary impact of management time dedicated to IPO preparations during FY18. Nevertheless, delivery of higher margin service ....
05 Mar 2018
Growth story on track
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Growth story on track
Fusion Antibodies Plc (FAB:LON) | 3.8 0 0.0% | Mkt Cap: 3.58m
- Published:
05 Mar 2018 -
Author:
Emma Ulker -
Pages:
2
Growth story on track Fusion Antibodies, a specialised Contract Research Organisation operating in the field of monoclonal antibody engineering and production, has provided an update on trading for the year ending 31 March 2018. It reports that FY18 revenues are expected to grow sizeably by at least 40% from £1.9m in FY17. This is slightly below expectations, due to the temporary impact of management time dedicated to IPO preparations during FY18. Nevertheless, delivery of higher margin service ....